In modern therapeutic antibody development, the ability to isolate naturally paired heavy and light chain antibody sequences from B cells is a decisive factor in generating fully human, high-affinity monoclonal antibodies (mAbs). Researchers now rely on innovative B-cell sorting workflows that combine precision, efficiency, and biological relevance. Among the most widely used strategies are...
In the world of genomic medicine, the CRISPR/Cas9 system is the ultimate "molecular scissor." However, even the sharpest tool is ineffective if it cannot reach its target. For researchers tackling complex diseases like lung tumors, the challenge has always been delivery.
To address this bottleneck, Creative Biolabs is hosting an exclusive webinar: "Optimization of Lipid Nanoparticles...
The landscape of immunotherapy has undergone a seismic shift over the last decade. While monoclonal antibodies (mAbs) laid the foundation for targeted treatment, the emergence of bispecific antibodies (BsAbs) has opened doors to therapeutic possibilities that were once deemed unreachable. By simultaneously binding to two different antigens or epitopes, BsAbs can bridge T-cells to tumor...
Abstract: As the global swine industry moves toward large-scale intensification, the demand for high-potency, high-purity vaccines has never been greater. This article explores the technical paradigm shift from traditional adherent cultures to fully enclosed suspension culture systems. We focus specifically on how this technology optimizes the production of Pseudorabies Virus...
In the fast-evolving landscape of biopharmaceuticals, we are moving past the era of trial-and-error. If 2024 was the year Generative AI captured the public imagination, 2025-2026 is the era where AI delivers on its promise in the wet lab. Nowhere is this more evident than in antibody drug discovery—a field once hampered by years of "design-make-test" cycles, now being streamlined by...
The field of drug development and cosmetic safety is undergoing a paradigm shift. For decades, the "Draize Test"—which involves applying substances directly to the eyes of rabbits—was the industry standard for assessing ocular irritation. However, ethical concerns and the physiological differences between species have driven a surge in demand for more human-relevant, ethical, and...
The human microbiome is no longer a "hidden organ" but a central pillar of modern precision medicine. As we move through 2026, the shift from merely mapping microbial diversity to engineering functional cures has birthed a rapidly expanding field: Live Biotherapeutic Products (LBPs). From the well-known Escherichia coli Nissle 1917 to complex microbial consortia, LBPs are redefining...
The landscape of modern medicine is shifting. As we move away from "one-size-fits-all" treatments toward precision medicine, the pressure on preclinical drug discovery has never been greater. For researchers, the challenge lies in bridging the gap between laboratory benchwork and human clinical trials. To succeed, drug developers are increasingly relying on a trio of critical pillars:...
As we progress through the first quarter of 2026, the landscape of targeted cancer therapy is undergoing a significant transformation. Among the most promising modalities, Antibody-Drug Conjugates (ADCs) continue to dominate the discussion, particularly with the emergence of high-affinity antibodies targeting the vascular endothelial growth factor receptor 2 (VEGFR2) and the integration of...
Question: How do mesenchymal stem cell-derived exosomes provide therapeutic benefits for neonatal Bronchopulmonary Dysplasia? Answer: BPD is characterized by impaired alveolar development and chronic inflammation in premature infants. Research indicates that MSC-derived exosomes can effectively modulate the inflammatory response and promote lung tissue repair by delivering bioactive lipids,...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek